Altre lingue BridgeBio Pharma, Inc.

Azioni

BBIO

US10806X1028

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 19/04/2024			Variaz. 5gg	Var. 1 gen.
24,74 ^USD	-0,84%		-7,79%	-38,72%

07/04	BridgeBio Pharma, Inc. Presenta prove di imaging a risonanza magnetica cardiaca (CMR) coerenti con il miglioramento clinico	CI
21/03	BRIDGEBIO PHARMA, INC. : JPMorgan Chase ribadisce il giudizio positivo sul titolo	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	10/04
BridgeBio Pharma Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 study in Patients with Transthyretin Amyloid Cardiomyopathy	08/04
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	07/04
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	07/04
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	07/04
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	20/03
BridgeBio Pharma : BBIO – Encaleret for ADH1 – ACMG 2024 Genetic Testing	14/03
BridgeBio Pharma Prices $250 Million Stock Offering	06/03
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock	06/03
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	05/03
BridgeBio Pharma Commences $250 Million Share Offering	04/03
BridgeBio Pharma Announces Proposed Public Offering of Common Stock	04/03
BridgeBio Pharma Sells License for Potential Heart Disease Treatment to Bayer in Deal Worth up to $310 Million	04/03
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	04/03
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe	04/03
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	04/03
Bridgebio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	04/03
BridgeBio Pharma : BBIO – BBP-418 – MDA 2024 – Development of PROMIS Tool	01/03
BridgeBio Pharma : BBIO – BBP-418 – MDA 2024 – FORTIFY Phase 3 Trial Design	27/02
BridgeBio Pharma Q4 Loss Widens as Revenue Declines	22/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue BridgeBio Pharma, Inc.

Azioni

BBIO

US10806X1028

Altre lingue

Filtri